Randomised controlled trial of two implantable contraceptives: Jadelle and Implanon

Conditions

Contraception Pregnancy and Childbirth Contraception

Ali M, Akin A, Bahamondes L, Brache V, Habib N, Landoulsi S, Hubacher D, WHO study group on subdermal contraceptive implants for women.

2016-09-2675 citations

10.1093/humrep/dew222

A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls

Luís Bahamondes, Vivian Brache, Olav Meirik, Moazzam Ali, Ndema Habib et al. (6 authors)

Human Reproduction2015-09-25102 citations

10.1093/humrep/dev221

Interventions

Jadelle, Implanon, TCu380A (for the observational cohort).

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. General good health 2. Age between 18 and 44 years 3. Not pregnant 4. Requesting long-term reversible contraception 5. Able to keep a menstrual diary 6. Willing to return for follow-up

Exclusion criteria

Exclusion criteria: 1. Breastfeeding an infant less than six weeks 2. High blood pressure 3. Current venous thromboembolism 4. Ischaemic heart disease 5. Vaginal bleeding 6. History of breast cancer

Design outcomes

Primary

Measure	Time frame
1. Pregnancies 2. Adverse events 3. Method continuation rates 4. Incidence of complaints reportedly associated with implant contraception 5. Vaginal bleeding patterns Follow-up duration for primary endpoints: three years.	—

Secondary

Measure	Time frame
No secondary outcome measures	—

Countries

Brazil, Chile, China, Dominican Republic, Hungary, Slovenia, Thailand, Turkey, Zimbabwe

Outcome results

None listed